FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042756409> ?p ?o ?g. }

• W2042756409 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCTriple negative breast cancer (TNBC) patients suffer from a highly malignant and aggressive cancer that currently has no efficacious therapy. These patients have a high rate of relapse and often develop resistance to chemotherapy. Many TNBCs, both in vitro and in vivo, have elevated levels of epidermal growth factor receptor (EGFR) but are resistant to EGFR inhibitors as a monotherapy. The TNBC cell line, BT20, has increased levels of EGFR and is resistant to EGFR inhibitors. To identify the signaling pathways that remain phosphorylated after treatment with gefitinib, an EGFR tyrosine kinase inhibitor (TKI), we used mass spectrometry based phospho-proteomics. Through these assays we identified many components of the mTOR pathway phosphorylated in the presence of gefitinib and further sought to explore this pathway as a mechanism of resistance to EGFR inhibitors in TNBC. mTOR inhibitors have been investigated in the clinic due to their ability to inhibit the PI3Kinase/Akt pathway thus decreasing cell survival and proliferation. Inhibiting mTOR also importantly inhibits translation. Despite activation of these pathways our TNBC cell lines, BT20, MDA-MB-123, and MDA-MB-468 are resistant to temsirolimus, an mTOR inhibitor. Our studies have found that dual treatment with an mTOR inhibitor and an EGFR TKI has a synergistic effect on decreasing TNBC cell viability, but the mechanism of this synergy is not understood. We have found that the abrogation of both EGFR and mTOR signaling does not alter the phosphorylation status of key signaling pathways including MAPK and Akt. Instead, our preliminary data have identified the translational control protein eIF4B as potentially key fragile point in EGFR and mTOR inhibitor synergy. Therefore, in this study we hypothesized that mTOR inhibition will sensitize TNBC cells to EGFR TKIs through the inhibition of eIF4B phosphorylation. Small molecules have yet to be identified to abrogate the function of eIF4B, which when phosphorylated enhances the helicase activity of eIF4A critical to translation. Therefore, we knockdown eIF4B expression and found a decrease in cell survival comparable to the decrease observed with gefitinib and temsirolimus treatment. In addition, we have identified p70S6K and p90RSK as kinases directly responsible for eIF4B phosphorylation, such that both molecules need to be inactivated in order for eIF4B phosphorylation to be inhibited. This inactivation correlates with a loss of cell growth and viability and a decrease in clonogenic cell survival. Lastly, we have shown that the downstream functions of eIF4B phosphorylation are abrogated with EGFR and mTOR inhibitors. Therefore, taken together these data suggest that in the presence of activated MAPK and AKT, EGFR and mTOR inhibitors have the ability to abrogate cell growth, viability, and survival via disruption of the translational control mechanisms through eIF4B.Citation Format: Julie Madden, Kelly Mueller, Aliccia Bollig-Fischer, Paul Stemmer, Julie Boerner. Combating resistance to EGFR inhibitors: eIF4B as a novel target. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1026. doi:10.1158/1538-7445.AM2013-1026" @default.
• W2042756409 created "2016-06-24" @default.
• W2042756409 creator A5033688288 @default.
• W2042756409 creator A5044158880 @default.
• W2042756409 creator A5049983845 @default.
• W2042756409 creator A5077371055 @default.
• W2042756409 creator A5085966748 @default.
• W2042756409 date "2013-04-15" @default.
• W2042756409 modified "2023-09-26" @default.
• W2042756409 title "Abstract 1026: Combating resistance to EGFR inhibitors: eIF4B as a novel target." @default.
• W2042756409 doi "https://doi.org/10.1158/1538-7445.am2013-1026" @default.
• W2042756409 hasPublicationYear "2013" @default.
• W2042756409 type Work @default.
• W2042756409 sameAs 2042756409 @default.
• W2042756409 citedByCount "0" @default.
• W2042756409 crossrefType "proceedings-article" @default.
• W2042756409 hasAuthorship W2042756409A5033688288 @default.
• W2042756409 hasAuthorship W2042756409A5044158880 @default.
• W2042756409 hasAuthorship W2042756409A5049983845 @default.
• W2042756409 hasAuthorship W2042756409A5077371055 @default.
• W2042756409 hasAuthorship W2042756409A5085966748 @default.
• W2042756409 hasConcept C121608353 @default.
• W2042756409 hasConcept C126322002 @default.
• W2042756409 hasConcept C183713625 @default.
• W2042756409 hasConcept C185592680 @default.
• W2042756409 hasConcept C2776820818 @default.
• W2042756409 hasConcept C2777506169 @default.
• W2042756409 hasConcept C2779438470 @default.
• W2042756409 hasConcept C2780110267 @default.
• W2042756409 hasConcept C2780580887 @default.
• W2042756409 hasConcept C502942594 @default.
• W2042756409 hasConcept C530470458 @default.
• W2042756409 hasConcept C55493867 @default.
• W2042756409 hasConcept C62478195 @default.
• W2042756409 hasConcept C71924100 @default.
• W2042756409 hasConcept C75217442 @default.
• W2042756409 hasConcept C86554907 @default.
• W2042756409 hasConcept C98274493 @default.
• W2042756409 hasConceptScore W2042756409C121608353 @default.
• W2042756409 hasConceptScore W2042756409C126322002 @default.
• W2042756409 hasConceptScore W2042756409C183713625 @default.
• W2042756409 hasConceptScore W2042756409C185592680 @default.
• W2042756409 hasConceptScore W2042756409C2776820818 @default.
• W2042756409 hasConceptScore W2042756409C2777506169 @default.
• W2042756409 hasConceptScore W2042756409C2779438470 @default.
• W2042756409 hasConceptScore W2042756409C2780110267 @default.
• W2042756409 hasConceptScore W2042756409C2780580887 @default.
• W2042756409 hasConceptScore W2042756409C502942594 @default.
• W2042756409 hasConceptScore W2042756409C530470458 @default.
• W2042756409 hasConceptScore W2042756409C55493867 @default.
• W2042756409 hasConceptScore W2042756409C62478195 @default.
• W2042756409 hasConceptScore W2042756409C71924100 @default.
• W2042756409 hasConceptScore W2042756409C75217442 @default.
• W2042756409 hasConceptScore W2042756409C86554907 @default.
• W2042756409 hasConceptScore W2042756409C98274493 @default.
• W2042756409 hasLocation W20427564091 @default.
• W2042756409 hasOpenAccess W2042756409 @default.
• W2042756409 hasPrimaryLocation W20427564091 @default.
• W2042756409 hasRelatedWork W13524344 @default.
• W2042756409 hasRelatedWork W1883752949 @default.
• W2042756409 hasRelatedWork W1974120504 @default.
• W2042756409 hasRelatedWork W2019166951 @default.
• W2042756409 hasRelatedWork W2025432838 @default.
• W2042756409 hasRelatedWork W2045571277 @default.
• W2042756409 hasRelatedWork W2052468128 @default.
• W2042756409 hasRelatedWork W2071749956 @default.
• W2042756409 hasRelatedWork W2081384538 @default.
• W2042756409 hasRelatedWork W2130777678 @default.
• W2042756409 hasRelatedWork W2317079644 @default.
• W2042756409 hasRelatedWork W2740737303 @default.
• W2042756409 hasRelatedWork W2887102075 @default.
• W2042756409 hasRelatedWork W2955528839 @default.
• W2042756409 hasRelatedWork W2966274794 @default.
• W2042756409 hasRelatedWork W2974416662 @default.
• W2042756409 hasRelatedWork W3162173207 @default.
• W2042756409 hasRelatedWork W841794138 @default.
• W2042756409 hasRelatedWork W856819346 @default.
• W2042756409 hasRelatedWork W996184470 @default.
• W2042756409 isParatext "false" @default.
• W2042756409 isRetracted "false" @default.
• W2042756409 magId "2042756409" @default.
• W2042756409 workType "article" @default.